Aurora Spine completed patient enrollment in its REFINE study of the ZIP Interspinous Fixation device for patients with symptomatic degenerative disc disease. This U.S. prospective, multi-center, multi-specialty clinical trial is the first of its kind to evaluate the safety and efficacy of lumbar interlaminar fusion devices, marking a significant milestone in the advancement of spinal care.
ZIP MIS Interspinous Fusion aims to address unmet needs in treating lumbar spinal stenosis and degenerative disc disease, offering patients a less invasive alternative to traditional spinal surgery.
Trent Northcutt, President and CEO of Aurora Spine, said, “Completing enrollment in the REFINE study underscores our dedication to advancing spinal health through cutting-edge technology and rigorous clinical research. We look forward to sharing the results with the medical community at ASPN in July and continuing to drive innovation that transforms lives.”
Aurora Spine completed patient enrollment in its REFINE study of the ZIP Interspinous Fixation device for patients with symptomatic degenerative disc disease. This U.S. prospective, multi-center, multi-specialty clinical trial is the first of its kind to evaluate the safety and efficacy of lumbar interlaminar fusion devices, marking a significant...
Aurora Spine completed patient enrollment in its REFINE study of the ZIP Interspinous Fixation device for patients with symptomatic degenerative disc disease. This U.S. prospective, multi-center, multi-specialty clinical trial is the first of its kind to evaluate the safety and efficacy of lumbar interlaminar fusion devices, marking a significant milestone in the advancement of spinal care.
ZIP MIS Interspinous Fusion aims to address unmet needs in treating lumbar spinal stenosis and degenerative disc disease, offering patients a less invasive alternative to traditional spinal surgery.
Trent Northcutt, President and CEO of Aurora Spine, said, “Completing enrollment in the REFINE study underscores our dedication to advancing spinal health through cutting-edge technology and rigorous clinical research. We look forward to sharing the results with the medical community at ASPN in July and continuing to drive innovation that transforms lives.”
Copy to clipboard 
